literature

HIV mutation literature information.

Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.

PMID: 23480551 2013 Clinical microbiology and infection

Abstract: The concordance rates between the RFMP and direct sequencing assays for the examined codons were 97% (K65R), 97% (T69Ins/D), 97% (L74VI), 97% (K103N), 96% (V106AM), 97% (Q151M), 97% (Y181C), 97% (M184VI) and 94% (T215YF) in the reverse transcriptase coding region, and 100% (D30N), 100% (M46I), 100% (G48V), 100% (I50V), 100% (I54LS), 99% (V82A), 99% (I84V) and 100% (L90M) in th

Transmitted HIV drug resistance in treatment-naive Romanian patients.

PMID: 23592112 2013 Journal of medical virology

Result: The Q151M multinucleoside resistance complex, which causes high or intermediate-level resistance to all NRTIs was not present.

Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.

PMID: 24009694 2013 PloS one

Table: Q151M

Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana.

PMID: 24119088 2013 BMC infectious diseases

Table: Q151M

Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina.

PMID: 24093951 2013 Journal of the International AIDS Society

Method: Sequences were analyzed to identify mutations associated with reduced susceptibility to protease and RT inhibitors, as reported by the International AIDS Society-USA in 2010: RT-M41L, A62V, K65R, D67N, 69 insert, K70R, L74V,V75I, F77L, L100I, K101P, K103N, V106A, V106M, V108I, Y115F, F116Y,

Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic.

PMID: 24215971 2013 AIDS research and therapy

Discussion: In the same study M184V/I occurred in 84%, K65R in 11%, and Q151M in 5% with TAMs occurring in 18% of the NRTIs resistance mutations.

Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.

PMID: 24015311 2013 PloS one

Result: Finally, the Q151M and K65R mutations were positively associated to each other.

Result: In multivariate analysis, besides higher HIV-1 RNA VL level, probably associated with longer duration of failure, we found that d4T-use remained independently associated with the presence of MNR mutations (either Q151M or K65R).

Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in India.

PMID: 23735817 2013 Journal of the International AIDS Society

Result: During this time, seven additional participants developed M184V, three developed 69 insertion site mutations and two developed Q151M.

Table: Q151M

Chemical system biology based molecular interactions to identify inhibitors against Q151M mutant of HIV-1 reverse transcriptase.

PMID: 24015311 2013 PloS one

Introduction: Q151M confers resistance to all NRTIs, except tenofovir (TDF).

Result: A high HIV-1 RNA level was also significantly associated with Q151M (p<0.0001).

Result: In multivariate analysis, independent risk factors for Q151M were d4T-containing regimen (Odds ratio (OR) [95% confidence interval (CI)]: 2.21 [1.05-4.65]), high HIV-1 RNA level (OR [95% CI]: 4.02 [2.13-7.59]), and duration >30 months under current first-line regimen (OR [95% CI]: 2.11 [1.18-3.76]) (table 1).

Persistence of HIV-1 transmitted drug resistance mutations.

PMID: 23904291 2013 The Journal of infectious diseases

Table: Q151M

Browser Board

Co-occurred Entities

Filtrator